A rare, genetic hemoglobinopathy characterized by all the characteristics of sickle cell anemia (SCA). Clinical course is similar to SCA, including acute episodes of pain, splenic infarction and splen...
Comprehensive, easy-to-understand information about this condition
How we create this content →SCDAA is the premier organization advocating for people with sickle cell disease.
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
European rare disease database
Genetic and Rare Diseases Info Center
SCDAA is the premier organization advocating for people with sickle cell disease.
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
European rare disease database
Genetic and Rare Diseases Info Center
Connect with organizations supporting the sickle cell-hemoglobin d disease syndrome community
Helpful links for rare disease information and support
Questions that may be helpful when speaking with your healthcare team
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Feb 5, 2026
SCDAA is the premier organization advocating for people with sickle cell disease.
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
European rare disease database
Genetic and Rare Diseases Info Center
2 peer-reviewed sources from PubMed
AI-Generated Content: This summary was generated using AI. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 11 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
AI-curated news mentioning sickle cell-hemoglobin d disease syndrome
Updated Feb 18, 2026
A retrospective study from Türkiye compares mortality and complications after total hip arthroplasty in patients with sickle cell disease. The findings contribute to understanding surgical risks in this patient population.
Vertex Pharmaceuticals and CRISPR Therapeutics project that revenues from Casgevy, a gene therapy for sickle cell disease and beta thalassemia, will nearly triple by 2026 as patient access improves. This ambitious goal follows a year of slow uptake for the therapy.
Yale School of Medicine discusses the potential of gene-editing treatments for rare genetic diseases, highlighting the FDA's recent approval of a CRISPR-based therapy for sickle cell disease in 2023. This marks a significant advancement in the application of CRISPR technology.
The S 735 bill, aimed at enhancing research, surveillance, prevention, and treatment for sickle cell disease and other heritable blood disorders, has been introduced and referred to the Committee on Health, Education, Labor, and Pensions. This legislative move could impact funding and focus on these conditions.
The House has introduced HR 1796, aimed at enhancing research, surveillance, prevention, and treatment for sickle cell disease and other heritable blood disorders. The bill has been referred to the House Committee on Energy and Commerce for further consideration.